Please use this identifier to cite or link to this item:
http://ir.mu.ac.ke:8080/jspui/handle/123456789/3288
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ballif, M. | - |
dc.contributor.author | Nhandu, V. | - |
dc.contributor.author | Wood, R. | - |
dc.contributor.author | Dusingize, J. C. | - |
dc.contributor.author | Carter, E. J. | - |
dc.contributor.author | Cortes, C. P. | - |
dc.contributor.author | McGowan, C. C. | - |
dc.contributor.author | Diero, L. | - |
dc.contributor.author | Graber, C. | - |
dc.contributor.author | Renner, L. | - |
dc.contributor.author | Hawerlander, D. | - |
dc.contributor.author | Kiertiburanakul, S. | - |
dc.contributor.author | Du, Q. T. | - |
dc.contributor.author | Sterling, T. R. | - |
dc.contributor.author | Egger, M. | - |
dc.contributor.author | Fenner, L | - |
dc.date.accessioned | 2020-08-04T06:46:02Z | - |
dc.date.available | 2020-08-04T06:46:02Z | - |
dc.date.issued | 2014 | - |
dc.identifier.uri | https://doi.org/10.5588/ijtld.14.0106 | - |
dc.identifier.uri | http://ir.mu.ac.ke:8080/jspui/handle/123456789/3288 | - |
dc.description.abstract | SETTING: Drug resistance threatens tuberculosis (TB) control, particularly among human immunodeficiency virus (HIV) infected persons. OBJECTIVE: To describe practices in the prevention and management of drug-resistant TB under antiretroviral therapy (ART) programs in lower-income countries. DESIGN: We used online questionnaires to collect program-level data on 47 ART programs in Southern Africa (n = 14), East Africa (n = 8), West Africa (n = 7), Central Africa (n = 5), Latin America (n = 7) and the Asia-Pacific (n = 6 programs) in 2012. Patient-level data were collected on 1002 adult TB patients seen at 40 of the participating ART programs. RESULTS: Phenotypic drug susceptibility testing (DST) was available in 36 (77%) ART programs, but was only used for 22% of all TB patients. Molecular DST was available in 33 (70%) programs and was used in 23% of all TB patients. Twenty ART programs (43%) provided directly observed therapy (DOT) during the entire course of treatment, 16 (34%) during the intensive phase only, and 11 (23%) did not follow DOT. Fourteen (30%) ART programs reported no access to second-line anti-tuberculosis regimens; 18 (38%) reported TB drug shortages. CONCLUSIONS: Capacity to diagnose and treat drug-resistant TB was limited across ART programs in lower-income countries. DOT was not always implemented and drug supplies were regularly interrupted, which may contribute to the global emergence of drug resistance. | en_US |
dc.language.iso | en | en_US |
dc.publisher | International Union Against Tuberculosis and Lung Disease | en_US |
dc.subject | ART programs | en_US |
dc.subject | Africa | en_US |
dc.subject | Asia | en_US |
dc.subject | MDR-TB | en_US |
dc.title | Detection and management of drug-resistant tuberculosis in HIV-infected patients in lower-income countries | en_US |
dc.type | Article | en_US |
Appears in Collections: | School of Medicine |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.